Global Oncolytics Virus Threapy Market

CHESTER, N.Y. - March 13, 2018 - PRLog -- Global Oncolytic Virus Therapy Market report published by Data M Intelligence:Industry Insights and Forecast to 2025

Data M Intelligence has announced its publication of global oncolytic virus therapy market research study. This report includes market size, market share, current market trends, industry competition, key player analysis and year-on-year market forecasts from 2018 to 2025.

According to recent studies, there has been a rapid growth in clinical trails environment for the oncolytic virus. Till date, only one oncolytic virus –a genetically modified form of herpesvirus for treating melanoma has been approved by the US food and drug administration(FDA).

It is estimated that Talimogene laherparepvec drug dominates the market by the end of 2025. Merck, one of the leading market players, has agreed to buy this virus-based cancer drug from viralytics for USD 394 million in 2018.

By Geography, North America accounted for the most significant market share in terms of market value in 2017,  while the Asia-pacific market is estimated to grow at a faster rate over the coming five years", quoted the research analyst at DMI, while describing the future demand in the market.

The global oncolytic virus therapy market is segmented by clinical trial analysis, by drug class, and by geography. Investments in R&D is one of the most critical strategies adopted by the major companies for increasing their revenue and market share.

Most Active Companies: Pfizer, Viralytics, Roche, Merck.

Know more at : https://www.datamintelligence.com/research-report/global-...